Gain Therapeutics, Inc. (GANX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol GANX
- Company Gain Therapeutics, Inc.
- Price $2.51
- Changes Percentage 19.86
- Change 0.42
- Day Low $2.09
- Day High $2.59
- Year High $4.34
- Year Low $1.41
- Market Cap $96,347,523
- Price Avg 50 EMA (D) $2.49
- Price Avg 200 EMA (D) $2.09
- Exchange NASDAQ
- Volume 1,538,233
- Average Volume 1,309,005
- Open $2.1
- Previous Close $2.09
- EPS -0.61
- PE -4.11
- Earnings Announcement 2026-03-19 12:00:00
- Shares Outstanding $38,462,085
Company brief: GAIN THERAPEUTICS, INC. (GANX )
- Healthcare
- Biotechnology
- Mr. Matthias Alder LIC. IUR., LL.M.
- https://www.gaintherapeutics.com
- US
- N/A
- 03-19-2021
- US36269B1052
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.